



Government **B**ioscience **G**rants

UPDATED MONTHLY

May 22, 2020

THE ESSENTIAL GUIDE TO

# Coronavirus Government Funding

PUBLISHED BY



## Questions?

Liz Powell, Esq., MPH


[lpowell@G2Gconsulting.com](mailto:lpowell@G2Gconsulting.com)






[www.G2Gconsulting.com](http://www.G2Gconsulting.com)



[@G2Gconsulting](https://twitter.com/G2Gconsulting)



## COVID-19 Coronavirus





<http://www.g2gconsulting.com/bioscience-corner>

**\*Special Edition\***  
**Coronavirus Funding and Resources Report**

May 22, 2020

G2G has been tracking daily the coronavirus response funding and legislation and this is our second Special Edition GBG Report, The Essential Guide to Coronavirus Government Funding. For the past three months we have been hosting a weekly series of webinars to help businesses, start-ups, nonprofits, and innovative companies and entrepreneurs stay up-to-date on the latest R&D grants, forgivable and low-interest loans, tax credits and other programs and policies enacted to help states, businesses, nonprofits and individuals during this unprecedented time. We are also providing guidance on how to access the billions of dollars in new non-dilutive government funding. Click [here](#) to explore upcoming webinars and to register.

We will continue to provide updates in our [Twitter posts](#) and in our [Legislative Updates](#) and on [G2G's LinkedIn account](#).

In this Report you will find current, upcoming, and past (closed) COVID-19-related funding opportunities and resources listed by agency in alphabetical order. Please let us know any questions by contacting Liz Powell at [lpowell@G2Gconsulting.com](mailto:lpowell@G2Gconsulting.com).

**TABLE OF CONTENTS**

AGENCY	PAGE	AGENCY	PAGE
Biomedical Advanced Research and Development Authority (BARDA)	2-3	Economic Development Administration (EDA)	9
Centers for Disease Control and Prevention (CDC)	3-4	Food and Drug Administration (FDA)	10
DOD Congressionally Directed Medical Research Programs (CDMRP)	4-5	Non-Governmental Organization (NGO)	10
DOD Medical CBRN Defense Consortium (MCDC)	5	National Institutes of Health (NIH)	10-30
DOD Medical Technology Enterprise Consortium (MTEC)	6	National Science Foundation (NSF)	31
DOD Small Business Innovation Research (SBIR)	6-7	Office of Science & Technology Policy (OSTP)	31
DOD U.S. Army Medical Research & Development Command (USAMRDC) and Army Applications Laboratory (AAL)	7-8	Patient-Centered Outcomes Research Institute (PCORI)	32
DOD U.S. Special Operations Command (USSOCOM)	8	Small Business Administration (SBA)	32
DOD xTechSearch	8-9	Other – Biotechnology Innovation Organization (BIO)	32
Department of Homeland Security (DHS) Federal Emergency Management Agency (FEMA)	9	Other – BioOhio COVID-19 Resources for Bioscience Organizations	33

	Title	Opp. Number	Description	Deadline	Funding Level	Link
			<b>BARDA (3)</b>			
1.	Broad Agency Announcement	BAA-18-100-SOL-00003	<p>The BARDA Broad Agency Announcement is entirely focused on Coronavirus responses and the following areas of interest:</p> <ul style="list-style-type: none"> <li>• Diagnostic Assay for human coronavirus using existing FDA-cleared platforms</li> <li>• Point-of-Care Diagnostic Assay for detection of SARS-CoV-2 virus</li> <li>• Diagnostic Assay for detection of COVID-19 disease (SARS-CoV-2 infection)</li> <li>• COVID-19 Vaccine</li> <li>• COVID-19 Therapeutics</li> <li>• Immunomodulators or therapeutics targeting lung repair</li> <li>• Pre-exposure and Post-exposure Prophylaxis</li> <li>• Respiratory Protective Devices</li> <li>• Ventilators</li> </ul> <p>BARDA will only accept submissions related to the SARS-CoV-2 virus or the COVID-19 disease until further notice.</p>	White Papers Due: 7/31/20, 10/31/20	Up to \$8 million, Dependent upon proposal	<a href="https://beta.sam.gov/opp/1b46a4169fcb4902b9c4fcbb5bf981f7/view">https://beta.sam.gov/opp/1b46a4169fcb4902b9c4fcbb5bf981f7/view</a>
2.	EZ BAA, Division of Research, Innovation & Ventures (DRIVE) Easy Broad Agency Announcement	BAA-20-100-SOL-0002	<p>To spur innovation, BARDA has issued its business-friendly, streamlined Easy Broad Agency Announcement (EZ-BAA) to support a number of new medical countermeasures to fight the COVID-19 outbreak. Under the EZ-BAA, BARDA is looking for:</p> <ul style="list-style-type: none"> <li>• Molecular diagnostic assay for SARS-CoV-2 virus on existing FDA-cleared platform</li> <li>• Point-of-care diagnostic assay for detection of SARS-CoV-2 virus</li> <li>• Diagnostic assay for detection of COVID-19 disease</li> <li>• Nonclinical model development and screening for SARS-CoV-2 virus</li> <li>• Alternate vaccine delivery/administration and adjuvants</li> <li>• Advanced manufacturing technologies</li> </ul>	Proposals accepted on rolling basis	Up to \$750,000 for up to 2 years	<a href="https://beta.sam.gov/opp/b4f7923443a448218d369209723141c5/view?keywords=BAA-20-100-SOL-0002%20&amp;sort=-relevance&amp;index=&amp;is_active=true&amp;page=1">https://beta.sam.gov/opp/b4f7923443a448218d369209723141c5/view?keywords=BAA-20-100-SOL-0002%20&amp;sort=-relevance&amp;index=&amp;is_active=true&amp;page=1</a>

3.	CoronaWatch Requests	N/A	<p style="text-align: center;"><b>BARDA</b></p> <p>Seeks information from stakeholders on available medical countermeasures in development, particularly interested in products and technologies that have progressed into or beyond non-clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform. Information regarding diagnostics, therapeutics, vaccines, and other products or technologies relevant to addressing this outbreak are sought. Items to submit include: Brief description of your product or technology, accompanied by a slide deck, manuscript, publications, or other non-confidential information you think will be helpful. Ideal technologies and products would (but are not required to) be:</p> <ul style="list-style-type: none"> <li>• Relevant to the U.S. government COVID-19 medical countermeasure research and development efforts and/or Emerging Infectious Disease rapid response capabilities</li> <li>• Utilize an already-approved platform, have non-clinical data suggesting efficacy, and/or have significant manufacturing capability</li> <li>• Fully owned or licensed by your organization (you have full IP rights and/or freedom to operate)</li> </ul>	On-going	Dependent upon proposal	<a href="https://www.mediccountermeasures.gov/request-barda-techwatch-meeting/">https://www.mediccountermeasures.gov/request-barda-techwatch-meeting/</a>
			<b>CDC (3)</b>			
4.	CDC Programs and Information	N/A	The CDC has several COVID-19 resources and information on its website including: Symptoms and Testing; Frequently Asked Questions; Cases and Surveillance; Schools, Workplaces and Community Locations; Healthcare Professionals; Health Departments; Laboratories; and Communication Resources.	N/A	N/A	<a href="https://www.cdc.gov/coronavirus/2019-ncov/index.html">https://www.cdc.gov/coronavirus/2019-ncov/index.html</a>
5.	Pre-Announcement ATSDR's Partnership to Promote Local Efforts To Reduce Environmental Exposure - COVID-19 Supplement	CDC-RFA-TS20-20010101 SUPP20	The purpose of this funding announcement is to support state health departments in their response to the COVID-19 pandemic. Potential COVID-19 related work under this supplemental funding opportunity may include providing guidance and engagement on safe practices for disinfection for home, school and early learning education centers, and assist in COVID-19 response and prevention efforts by conducting environmental assessments, establishing plans for addressing environmental impacts, and strengthening partnerships among the environmental, epidemiological, and laboratory responses.	Estimated Post Date: 5/1/20  Estimated Proposal Due Date: 5/8/20	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=326478">https://www.grants.gov/web/grants/view-opportunity.html?opId=326478</a>

6.	(*Closed) Centers for Disease Control COVID-19 Broad Agency Announcement	75D301- 20-R- 67897	<b>CDC</b> The Centers for Disease Control and Prevention issued this BAA that was open for 14 days starting March 11 and was an immediate call for White Papers addressing the following focus areas: Surveillance, natural history, and household transmission; Diagnostics development and novel technology development and evaluation to improve diagnostic testing and detection; Immune response and transmission dynamics; Host infection dynamics; and Prospective Cohorts to Assess COVID-19 and Other Respiratory Diseases (ID/EPB).	Closed: 3/25/20	Dependent upon Proposal	<a href="https://beta.sam.gov/opp/728e1131ef444abc880f63540a37c364/view">https://beta.sam.gov/opp/728e1131ef444abc880f63540a37c364/view</a>
<b>DOD CDMRP (3)</b>						
7.	FY20 Peer Reviewed Medical Program (PRMRP) Clinical Trial Award (for Emerging Viral Diseases and Respiratory Health)	W81XW H-20- PRMRP- CTA- COV	This PRMRP Clinical Trial Award supports rapid implementation of clinical trials of novel interventions with the potential to have a significant impact on patient care in the Topic Areas of Emerging Viral Diseases and/or Respiratory Health. Applications must address at least one of the <a href="#">Focus Areas</a> published in the Program Announcement. Proposed projects may range from small proof-of- concept trials through large-scale, definitive trials. IND or IDE applications to the FDA, if needed, should be submitted to the FDA before the PRMRP application submission deadline.	Pre- Application Due: 6/8/20  Proposal Due: 6/22/20	Dependent upon proposal, for up to 4 years	<a href="https://cdmrp.army.mil/funding/pa/FY20-PRMRP-CTA-COV.pdf">https://cdmrp.army.mil/funding/pa/FY20-PRMRP-CTA-COV.pdf</a>
8.	FY20 Peer Reviewed Medical Program (PRMRP) Investigator- Initiated Research Award (for Emerging Viral Diseases and Respiratory Health)	W81XW H-20- PRMRP- IIRA- COV	This PRMRP Investigator-Initiated Research Award supports research that will make an original and important contribution to the field of research and/or patient care in the Topic Areas of Emerging Viral Diseases and/or Respiratory Health. Applications must address at least one of the <a href="#">Focus Areas</a> published in the Program Announcement. A partnering PI option is available and no clinical trials will be funded with this award mechanism.	Pre- Application Due: 5/28/20  Proposal Due: 6/12/20	Up to \$1.6 million, for up to 4 years	<a href="https://cdmrp.army.mil/funding/pa/FY20-PRMRP-IIRA-COV.pdf">https://cdmrp.army.mil/funding/pa/FY20-PRMRP-IIRA-COV.pdf</a>

9.	FY20 Peer Reviewed Medical Program (PRMRP) Technology/Therapeutic Development Award (for Emerging Viral Diseases and Respiratory Health)	W81XW H-20-PRMRP-TTDA-COV	<p style="text-align: center;"><b>DOD CDMRP</b></p> <p>This PRMRP Technology/Therapeutic Development Award supports the translation of promising preclinical findings into clinical applications for prevention, detection, diagnosis, treatment, or quality of life in the Topic Areas of Emerging Viral Diseases and/or Respiratory Health. Applications must address at least one of the <a href="#">Focus Areas</a> published in the Program Announcement and must be product-oriented (e.g., device, drug, clinical guidelines) and the product(s) to be developed may be a tangible item, such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product. Clinical trials will not be funded with this award mechanism.</p>	<p>Pre-Application Due: 5/28/20</p> <p>Proposal Due: 6/12/20</p>	Up to \$4 million, for up to 4 years	<a href="https://cdmrp.army.mil/funding/pa/FY20-PRMRP-TTDA-COV.pdf">https://cdmrp.army.mil/funding/pa/FY20-PRMRP-TTDA-COV.pdf</a>
<b>DOD MCDC (1)</b>						
10.	(*Closed) Diagnostics, Surveillance, POC, Therapeutics, Prophylactics, Clinical Trials	N/A	<p>The Medical CBRN Defense Consortium (MCDC) is a consortium of traditional and non-traditional defense contractors, small businesses, for-profit and not-for-profit entities, and academic institutions brought together for rapid prototyping in order to support the Department of Defense’s medical pharmaceutical and diagnostic requirements as related to enhancing the mission effectiveness of military personnel. This announcement sought proposals to address COVID-19 in the following technical areas: 1) Prevention (prophylaxis, pretreatment and post-exposure prophylaxis), 2) Detection/Diagnosis (systems and devices to identify CBRN agents and assist in making medical decisions) and 3) Treatment (therapeutics for post-exposure and post-symptomatic).</p>	Closed: 4/6/20	N/A	<a href="https://ati.acqcenter.com/MCDC/BIDS.NSF/Start?ReadForm">https://ati.acqcenter.com/MCDC/BIDS.NSF/Start?ReadForm</a>

<b>DOD MTEC (4)</b>						
11.	Potential Topics for Upcoming Funding Announcements at MTEC	N/A	MTEC anticipates the potential for additional funding announcements related to the following topic areas: (1) Point-of-Care Diagnostics to Rapidly ID Infected Individuals, (2) Predictive Analytics that can Forecast Potential Hot Spots and Empower Decision Makers Response Actions.	To be determined	To be determined	<a href="https://www.mtec-sc.org/upcoming-solicitations/">https://www.mtec-sc.org/upcoming-solicitations/</a>
12.	(*Closed) Wearable Diagnostic for Detection of COVID-19 Infection	MTEC-20-12-COVID-19_Diagnos-tics	The goal of this RPP is to develop a wearable diagnostic capability for the pre-/very early symptomatic detection of COVID-19 infection. *Note: Pending successful completion of this effort, the Government may issue a noncompetitive follow-on production contract or transaction pursuant to 10 USC 2371b section f.	Closed: 5/13/20	Dependent upon proposal	<a href="https://www.mtec-sc.org/wp-content/uploads/2020/05/20-12-COVID19_Diagnos-tics-RPP-1.pdf">https://www.mtec-sc.org/wp-content/uploads/2020/05/20-12-COVID19_Diagnos-tics-RPP-1.pdf</a>
13.	(*Closed) National Emergency Telecritical Care Network (NETCCN) Project	MTEC-20-10-COVID-19_NETC CN_TAT RC	In support of COVID-19 response, the goal of this RPP is to support the rapid development, deployment and testing of the National Emergency Telecritical Care Network (NETCCN) - a cloudbased, low-resource, stand-alone health information management system for the creation and coordination of flexible and extendable “virtual critical care wards.” These high acuity, virtual wards would bring high-quality critical care capability to nearly every bedside, be it healthcare facility, field hospital, or gymnasium.	Closed: 4/27/20	Dependent upon proposal	<a href="https://www.mtec-sc.org/wp-content/uploads/2020/04/20-10-COVID-19_NETCCN-1.pdf">https://www.mtec-sc.org/wp-content/uploads/2020/04/20-10-COVID-19_NETCCN-1.pdf</a>
14.	(*Closed) Development of Treatments for COVID-19	MTEC-20-09-COVID-19_Treat-ment_MI DRP	This solicitation sought proposals for: Therapeutic(s) that can treat COVID-19; Treatments with potential application to the prevention of COVID-19 infection were desired; and Therapeutics that can be administered in a non-hospital environment were desired.	Closed: 4/8/20	Up to \$4 million, for up to 8 months	<a href="https://www.mtec-sc.org/wp-content/uploads/2020/03/20-09-COVID19_RPP.pdf">https://www.mtec-sc.org/wp-content/uploads/2020/03/20-09-COVID19_RPP.pdf</a>
<b>DOD SBIR (3)</b>						
15.	Department of the Navy (DON) SBIR Defense Industrial (DIB) Technology Acceleration	N/A	The DON seeks digital logistic support to ensure delivery of medical supplies, support and care. The logistics of providing medical supplies, support, and care during mass illness and casualties, whether due to pandemics like COVID-19 or natural disasters or war, faces numerous challenges, including knowledge of supply chains that provide raw materials to manufacturers, ability for manufactures to increase production rates or retool their factories to produce medical products, ability to obtain FDA approval, if required, and ability to obtain federal, state, and local government contracts in a timely manner. The Department of the Navy (DON) is also urgently seeking portable, small form factor communications capabilities that meet the requirements for rapid and coordinated response during the COVID-19 crisis.	Proposal Due: 5/28/20	Up to \$150,000, for up to 5 months for Phase I and up to \$1.7 million, for Phase II	<a href="https://www.navysbir.com/docs/NAVY-20.4-BAA-20200410_Final.pdf">https://www.navysbir.com/docs/NAVY-20.4-BAA-20200410_Final.pdf</a>

16.	Department of the Navy (DON) SBIR/STTR – COVID-19 Pivot	N/A	<p style="text-align: center;"><b>DOD SBIR</b></p> <p>The Department of Navy is soliciting SBIR/STTR abstracts for proposals addressing the ongoing COVID-19 pandemic. Send 250-word abstract to the Navy SBIR/STTR via email with the Subject line: “COVID-19 Pivot” to <a href="mailto:navy-sbir-sttr@navy.mil">navy-sbir-sttr@navy.mil</a>.</p>	Proposals accepted on rolling basis	Dependent upon Proposal	<a href="mailto:navy-sbir-sttr@navy.mil">navy-sbir-sttr@navy.mil</a>
17.	(*Closed) Small Business Innovation Research (SBIR) Program X20.R SBIR Commercial Solutions Opening (CSO) Air Force Ventures Direct to Phase II	AF20R-DCSO1	<p>The Air Force COVID-19 Operational Planning Team (OPT) has assembled to identify key interest areas supporting COVID-19 defeat and mitigation related to AF operations and activities. The areas of interest include: <b>Decision Support in Combating the Virus</b> (Social Media Analytics, Adware Proximity Algorithm, Mobile Application for Self-Reporting, Enterprise Tool for COVID Tracking); <b>Personnel Needs</b> (Tele-Ministry, Tele-Counseling, Tele-Health, ChatBots); <b>Readiness</b> (Readiness Impact Assessment Tools, Training Scheduling Optimization Tools); <b>Logistics</b> (Medical Resources Common Operational Picture to provide shared supply/demand for critical supplies and deploy AI to enable forecasting, match timing, and supply types with vendor and delivery method); <b>Medical</b> (Air and Surface Cleansing, COVID-19 Testing &amp; Management and Medical Supply Chain); <b>Blue Sky</b> (Solutions other than those listed above).</p>	Closed: 4/30/20	Up to \$1 million for up to 27 months	<a href="https://beta.sam.gov/opp/aa1fc86c0cde4352a8ca464ee5b3296c/view#description">https://beta.sam.gov/opp/aa1fc86c0cde4352a8ca464ee5b3296c/view#description</a>  <a href="https://www.afwerx.af.mil/sbir.html">https://www.afwerx.af.mil/sbir.html</a>  <a href="https://www.dodsbir-sttr.mil/submissions/login">https://www.dodsbir-sttr.mil/submissions/login</a>
<b>DOD USAMRDC/AAL (2)</b>						
18.	New Products and Ideas (NPI)	N/A	<p>The United States Army Medical Research and Development Command (USAMRDC) utilizes the NPI system as a mechanism to have visibility and evaluate new products and ideas, currently configured or in development. The NPI provides a means for DoD subject matter experts to assess these products and ideas, evaluate their applicability to USAMRDC's mission, and provide feedback to the submitter. It provides the vendor an opportunity to showcase their product or idea without needing to travel to Fort Detrick and without giving anyone an unfair competitive advantage. For submissions related to the current COVID-19 (Coronavirus) outbreak, please be sure to select the "Ideas/Products Related to Current COVID-19 Outbreak" category during the “Select a Submission Category” step.</p>	Proposals accepted on rolling basis	N/A	<a href="https://mrdc-npi.amedd.army.mil">https://mrdc-npi.amedd.army.mil</a>



19.	(*Closed) Army Applications Laboratory (AAL)	N/A	<b>DOD USAMRDC/AAL</b> USAMRDC is working with the Army Applications Laboratory (AAL) for support in helping us work through the large volume of COVID-19 proposals we are receiving and to utilize a central data collection point for Army Medicine. You can schedule a conversation with the AAL team through the site <a href="https://calendly.com/cv-aal">https://calendly.com/cv-aal</a> to discuss your product. We encourage you to reach out to AAL to schedule a discussion.	Closed	N/A	<a href="http://aal.army">http://aal.army</a>
<b>DOD USSOCOM (2)</b>						
20.	(*Closed) SOCOM COVID-19 Innovation Challenge	N/A	The Coronavirus (COVID-19) outbreak was declared a national emergency in the United States in accordance with section 201 of the National Emergencies Act. The Secretary of Defense announced several measures to protect the Joint Force and the Public and U.S. Commanders received delegated authority to make further decisions based on their own assessments in order to protect their people and ensure mission readiness. This open call for innovative capabilities addressed the impacts of COVID-19 on public safety and national security. The innovations and solutions collected will be shared by default with a wide network of Government personnel engaged in the current challenge.	Closed: 3/31/20	N/A	<a href="https://vulcan-sof.com/login/ng2/auth/login?requestedUrl=%2Fhome">https://vulcan-sof.com/login/ng2/auth/login?requestedUrl=%2Fhome</a>
21.	(*Closed) SOCOM DIY Hack-a-Vent Innovation Challenge	N/A	This Innovation Challenge sought low-cost, non-FDA approved, mechanical ventilation support systems that can be rapidly produced at local levels with widely available resources. The top 3 submissions were selected by a panel of experts and may be offered an opportunity to produce a functioning prototype by March 30, 2020.	Closed: 3/25/20	N/A	<a href="https://vulcan-sof.com/login/ng2/auth/login?requestedUrl=%2Fhome">https://vulcan-sof.com/login/ng2/auth/login?requestedUrl=%2Fhome</a>
<b>DOD xTECHSEARCH (2)</b>						
22.	(*Closed) Army xTechSearch COVID-19 Ventilator Challenge	N/A	The Army seeks a low-cost, readily manufacturable emergency ventilator to quickly augment ventilator capacity in the exigent COVID-19 pandemic. The technology solution must provide a rapid response breathing apparatus capable of short-term, rugged field operation. In addition, the ventilator must be low cost, require minimal components, with a small footprint, and designed for mass production. Ideally, the technology would support field hospitals that are still acquiring critical infrastructure such as generators, power distribution and pressurized oxygen.	Closed	Up to \$100,000 per award	<a href="https://www.xtechsearch.army.mil/">https://www.xtechsearch.army.mil/</a>  (Visit the xTech website for future innovation challenges)

23.	(*Closed) Army xTechSearch Medical Technologies	N/A	<b>DOD xTECHSEARCH</b> This opportunity requested technologies optimized for use in austere environments that prevent, diagnose, treat, mitigate, or cure infectious diseases, including COVID-19 in service members and/or provide immediate cardiopulmonary stabilization and advanced, autonomous life support.	Closed: 3/31/20	N/A	<a href="https://www.arl.army.mil/xtechsearch/">https://www.arl.army.mil/xtechsearch/</a>
			<b>DOD COVID-19 EMERGENCY PANDEMIC RESPONSES (1)</b>			
24.	Department of Defense Group Email	N/A	During the COVID-19 Coronavirus Emergency Pandemic Response period, industry and academia can send inquiries on how your company or institution can support the response to the DOD's Group Email Box (see column at right for the email address)	On-going	N/A	<a href="mailto:osd.pentagon.ousd-a-s.mbx.covid-19-industry@mail.mil">osd.pentagon.ousd-a-s.mbx.covid-19-industry@mail.mil</a>
			<b>DHS FEMA (2)</b>			
25.	COVID-19 PPE and Medical Supplies	70FA202 OR000000 11	This is a standing solicitation issued under unusual and compelling needs from which the Government contemplates multiple awards of IDIQs and/or Direct Contracts, Purchase Orders, and Blanket Purchase Agreements for the supplies deemed as urgent in the COVID-19 pandemic. Supplies include materials for diagnostics and testing, RNA extraction, general medical equipment and PPE.	On-going until 9/25/20	Dependent upon proposal	<a href="https://beta.sam.gov/opp/3e05e664e606486ca34d1a41b47ff0ff/view">https://beta.sam.gov/opp/3e05e664e606486ca34d1a41b47ff0ff/view</a>
26.	COVID-19 Offer of Medical Supplies or Equipment	1660- 0147	Donations of PPE – FEMA is working to marshal every source of medical supplies and equipment, and will work to facilitate your generous donation to ensure the availability of critical protective and lifesaving resources to the right place, at the right time, and in the right quantity for a Whole of Nation response to COVID-19.	On-going until 10/31/20	N/A	<a href="https://www.fema.gov/covid19offers">https://www.fema.gov/covid19offers</a>
			<b>EDA (1)</b>			
27.	FY 2020 EDA Public Works and Economic Adjustment Assistance Programs including CARES Act Funding	PWEAA2 020	Under this NOFO, EDA solicits applications from applicants in rural and urban areas to provide investments that support construction, non-construction, technical assistance, and revolving loan fund projects under EDA's Public Works and EAA programs. Grants and cooperative agreements made under these programs are designed to leverage existing regional assets and support the implementation of economic development strategies that advance new ideas and creative approaches to advance economic prosperity in distressed communities. EDA provides strategic investments on a competitive- merit-basis to support economic development, foster job creation, and attract private investment in economically distressed areas of the United States. Note: only non-profit entities are eligible to apply to this opportunity	Proposals accepted on rolling basis	Dependent upon Proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=321695">https://www.grants.gov/web/grants/view-opportunity.html?oppId=321695</a>  (See Related Documents Tab for Full Proposal)

FDA (1)						
28.	Coronavirus Treatment Acceleration Program (CTAP)	N/A	The FDA has created a special emergency program for possible therapies, the Coronavirus Treatment Acceleration Program (CTAP). It uses every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful. The FDA continues to support clinical trials that are testing new treatments for COVID so that we gain valuable knowledge about their safety and effectiveness. <b>Send requests for product development for proposed COVID-19 uses and drug development to: <a href="mailto:COVID19-productdevelopment@fda.hhs.gov">COVID19-productdevelopment@fda.hhs.gov</a>.</b>	On-going	Dependent upon proposal	<a href="https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap">https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap</a>
NGO (1)						
29.	COVID-19 Therapeutics Accelerator	N/A	Currently there are no approved treatments for COVID-19. This new initiative aims to fill that gap by accelerating and evaluating new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term. The partners are committed to equal access, ensuring treatments are accessible and affordable in low-resource settings. The COVID-19 Therapeutics Accelerator is a philanthropic initiative designed to coordinate R&D efforts, remove barriers to drug development and scale up treatments to address the pandemic. The COVID-19 Therapeutics Accelerator will not be conducting a traditional funding call. <b>To learn more about the funding process, or how to invest in the accelerator, contact <a href="mailto:therapeuticsaccelerator@gatesfoundation.org">therapeuticsaccelerator@gatesfoundation.org</a>.</b>	Open Now	Dependent upon proposal	<a href="https://www.therapeuticsaccelerator.org">https://www.therapeuticsaccelerator.org</a> (Background Information)  <a href="mailto:therapeuticsaccelerator@gatesfoundation.org">therapeuticsaccelerator@gatesfoundation.org</a> . (Send email to above address to learn more about the funding process)
NIH (101)						
30.	Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)	PA-20-135 NOT-AI-20-034	In order to rapidly improve our understanding and available control measures for SARS-CoV-2 and COVID-19, NIAID is encouraging the submission of applications to address research areas of interest including: Studies to identify optimal <i>in vitro</i> culture requirements and conditions; Development of reagents and assays for virus characterization; Development of animal models of SARS-CoV-2 infection suitable for screening vaccine and therapeutic candidates and/or pathogenesis studies; Studies on the evolution and emergence of SARS-CoV-2 viruses including the identification of factors that affect viral host-range and virulence. Click <a href="#">here</a> for the full list of research areas of interest.	On-going	Dependent upon proposal	<a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_Section_II_Award_1</a>  <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-034.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-034.html</a>

31.	Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)	PA-18-935  NOT-GM-20-025	<p style="text-align: center;"><b>NIH</b></p> <p>The National Institutes of Health (NIH) hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full FOA that funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for Urgent Competitive Revisions will be routed directly to the NIH awarding component listed on the NoA of the most recent parent award. Only applications submitted in response to an Urgent Guide Notice published by an IC will be allowed to apply to this FOA. For funding consideration for COVID-19 focused applications, applicants must include the relevant FOA information: NOT-GM-20-025.</p>	On-going until 2/5/21	Dependent upon proposal	<a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section_II._Award_1</a>  <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-GM-20-025.html">https://grants.nih.gov/grants/guide/notice-files/NOT-GM-20-025.html</a>
32.	Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)	NOT-AG-20-022  PA-18-591  PA-18-935	<p>NIA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19). The mission of NIA is to support and conduct genetic, biological, clinical, behavioral, social, and economic research on aging. This NOSI supports mission critical areas of research for NIA as they relate to the COVID-19 pandemic. In order to rapidly improve our understanding and available control measures for 2019-nCoV, NIA is encouraging the submission of applications for either Administrative Supplements (PA-18-591) or Competitive Revisions (PA-18-935) to active grants to address the following research areas of interest in the Divisions of Aging Biology (DAB), Neuroscience (DN), Geriatrics and Clinical Gerontology (DGCG) and Behavioral and Social Research (DBSR)</p>	Proposals accepted on rolling basis until 5/1/21	Dependent upon proposal, for up to 2 years	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AG-20-022.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AG-20-022.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_Section_II._Award_1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section_II._Award_1</a>

33.	Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative Innovation Award (U01 Clinical Trial Optional)	PAR-19-099; 100 NOT-TR-20-011	<p style="text-align: center;"><b>NIH</b></p> <p>The Clinical and Translational Science Award (CTSA) Program Collaborative Innovation Award (CCIA) supports collaborative research activities that develop innovative solutions that will improve the efficiency, quality and impact of turning laboratory, clinic and community observations into interventions that improve the health of individuals and the public. This funding opportunity announcement (FOA) will support investigators from three or more CTSA Program hub institutions to either: 1) form new collaborations, or to 2) significantly expand the scientific scope of existing collaborations, or to 3) engage new collaborators in pre-existing collaborations to solve a translational science problem no one hub can solve alone, or disseminate a solution to a translational science problem developed at one hub to other hubs, in so doing testing its robustness to different hub environments and structures and adapting it for further dissemination outside the CTSA Program consortium if appropriate. For funding consideration for COVID-19 focused applications, applicants must include the relevant FOA information: NOT-TR-20-011 Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need).</p>	<p>Letter of Intent Due: 6/10/20, 10/9/20, 2/8/21</p> <p>Proposal Due: 7/10/20, 11/9/20, 3/8/21</p>	Up to \$750,000, for up to 4 years	<p><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-19-099.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-19-099.html#_Section_II._Award_1</a></p> <p><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-19-100.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-19-100.html#_Section_II._Award_1</a></p> <p><a href="https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-011.html">https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-011.html</a></p>
34.	Limited Competition: Competitive Revision Awards for the Clinical and Translational Science Award (CTSA) Program (U54 Clinical Trial Optional)	PAR-19-337 NOT-TR-20-011	This FOA is to solicit competitive revision (formerly known as competitive supplement) applications from awardees with active Clinical and Translational Science Award (CTSA) Program hub awards (UL1) to support the demonstration, and/or dissemination, and/or implementation of highly innovative and impactful translational science projects that address the goals of the CTSA Program and are beyond the original scope of the approved parent project Under this competitive revision, only applications for revisions to the UL1 award are allowed. Revisions to the linked KL2 and/or the TL1 awards are not allowed. For funding consideration for COVID-19 focused applications, applicants must include the relevant FOA information: NOT-TR-20-011 (Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need).	<p>Letter of Intent Due: 8/25/20</p> <p>Proposal Due: 9/25/20</p>	Up to \$750,000 per year, for up to 3 years	<p><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-19-337.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-19-337.html#_Section_II._Award_1</a></p> <p><a href="https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-011.html">https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-011.html</a></p>

35.	Bench Testing Therapeutic/Indication Pairing Strategies (UG3/UH3)	PAR-17-465 NOT-TR-20-012	<p style="text-align: center;"><b>NIH</b></p> <p>This FOA invites applications for support of pre-clinical studies to repurpose existing experimental or FDA approved drugs or biologics (existing therapeutics) that have already begun or completed at least a Phase I trial. The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair. The initial UG3 award will support the development of milestone-driven rigorous, pre-clinical target engagement and/or efficacy studies. Once UG3 pre-clinical milestones have been met, the UH3 award may be made to support clinical trial planning: this includes complete planning, design, and preparation of the documentation necessary for implementation of Phase I and/or Phase II clinical trials for a new therapeutic use. For funding consideration for COVID-19 focused applications, applicants must include NOT-TR-20-012. (Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease)</p>	<p>Letter of Intent Due: 5/25/20</p> <p>Proposal Due: 6/26/20</p>	<p>Up to \$200,000 per year, for up to 2 years</p> <p>Dependent upon Funding Mechanism</p>	<p><a href="https://grants.nih.gov/grants/guide/pa-files/par-17-465.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/par-17-465.html#_Section_II._Award_1</a></p> <p><a href="https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-012.html">https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-012.html</a></p>
36.	Clinical Trial Planning: Therapeutic/Indication Pairing Strategies (U34) (Clinical Trial Not Allowed)	PAR-18-462 NOT-TR-20-012	<p>The purpose of this FOA is to support clinical trial planning for studies that will evaluate a therapeutic/indication pair for drug repurposing. The repurposing hypothesis should be generated using a developed method that is publicly available. Examples include independent crowdsourcing strategies or any website that lists experimental therapies (drugs or biologics) or use of computational algorithms. For funding consideration for COVID-19 focused applications, applicants must include NOT-TR-20-012. (Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19))</p>	<p>Letter of Intent Due: 9/16/20</p> <p>Proposal Due: 10/16/20</p>	<p>Up to \$225,000 per year, for 1 year</p>	<p><a href="https://grants.nih.gov/grants/guide/pa-files/par-18-462.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/par-18-462.html#_Section_II._Award_1</a></p> <p><a href="https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-012.html">https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-012.html</a></p>
37.	Clinic Testing Therapeutic/Indication Pairing Strategies (U01 Clinical Trial Required)	PAR-18-332 NOT-TR-20-012	<p>This FOA invites applications for support of clinical studies to repurpose existing drugs or biologics (therapeutics) that have already completed at least a Phase I trial for a different indication by the time an award is made. The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair. Projects should be supported by scientific evidence that modulation of a therapeutic target will have a positive impact on the disease/condition. The U01 award may be used for Phase I and/or Phase II clinical trials for a new therapeutic use to establish substantial evidence of efficacy and to establish evidence of safety for the new use. For funding consideration for COVID-19 focused applications, applicants must include NOT-TR-20-012. (Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19))</p>	<p>Letter of Intent Due: 9/5/20</p> <p>Proposal Due: 10/5/20</p>	<p>Up to \$3 million per year, for up to 3 years</p>	<p><a href="https://grants.nih.gov/grants/guide/pa-files/par-18-332.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/par-18-332.html#_Section_II._Award_1</a></p> <p><a href="https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-012.html">https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-012.html</a></p>

38.	Competitive Revision Supplements to Existing AHRQ Health Service Research (HSR) Grants and Cooperative Agreements to Evaluate Health System and Healthcare Professional Responsiveness to COVID-19 (Supplement - Clinical Trial Optional) (NIH)	PA-20-070	<p style="text-align: center;"><b>NIH</b></p> <p>The Agency for Healthcare Research and Quality (AHRQ) hereby notifies grantees holding active AHRQ awards, (except R13s, T32s, F32s), that funds are available for competitive revisions to meet immediate needs to help address timely health system and healthcare professional response to the COVID-19 public health crisis. This FOA does not include grants that were previously funded under FOAs supported by Patient Centered Outcome Research Trust Fund (PCOR TF) dollars (Please see FOA number PA-20-072, which is directed towards those grants). Applications must be responsive to AHRQ’s mission, which is to produce evidence to make health care safer, higher quality, more accessible, equitable and affordable, and to work with the U.S. Department of Health and Human Services (HHS) and with other partners to make sure that the evidence is understood and used. Within the mission, AHRQ’s specific priority areas of focus are detailed here: <a href="https://www.ahrq.gov/funding/policies/foaguidance/index.html">https://www.ahrq.gov/funding/policies/foaguidance/index.html</a>.</p>	Proposal Due: 5/29/20	Dependent upon proposal	<a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-070.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-070.html#_Section II. Award 1</a>
39.	Competitive Revision Supplements to Existing AHRQ Patient Centered Outcomes Research (PCOR) Grants and Cooperative Agreements to Evaluate Health System and Healthcare Professional Responsiveness to COVID-19 (Supplement - Clinical Trial Optional)	PA-20-072	<p>The Agency for Healthcare Research and Quality (AHRQ) hereby notifies grantees holding active AHRQ awards that were funded under the PCOR FOAs, (see above: Part 1. Overview Information, Activity Code list), that funds are available for competitive revisions to meet immediate needs to help address timely health system and healthcare professional response to the COVID-19 public health crisis. This FOA does not include grants that were awarded using AHRQ Health Service Research (HSR) dollars (please see FOA number PA-20-070, which is directed toward those grants). It is expected that competitive revision supplement requests will capitalize on the expertise of grant personnel and the institutional environment to expand the specific aims of the ongoing research to develop high-impact new knowledge concerning COVID-19.</p>	Proposal Due: 5/29/20	Dependent upon proposal	<a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-072.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-072.html#_Section II. Award 1</a>

40.	Rapid Acceleration of Diagnostics (RADx) Fast-Track Program for COVID-19 Test Development and Distribution Innovative Technologies to Increase U.S. Capacity for COVID-19 Testing	N/A	<p style="text-align: center;"><b>NIH</b></p> <p>The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is urgently soliciting proposals and can provide up to \$500M across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public's safe return to normal activities. Rapid Acceleration of Diagnostics (RADx), is a fast-track technology development program that leverages the National Institutes of Health (NIH) Point-of-Care Technology Research Network (POCTRN). RADx will support novel solutions that build the U.S. capacity for SARS-CoV-2 testing up to 100-fold above what is achievable with standard approaches. RADx is structured to deliver innovative testing strategies to the public as soon as late summer 2020 and is an accelerated and comprehensive multi-pronged effort by NIH to make SARS-CoV-2 testing readily available to every American.</p>	Proposals accepted on a rolling basis	Dependent upon proposal	<a href="https://www.poctrn.org/radx">https://www.poctrn.org/radx</a>
41.	Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences	NOT-OD-20-097 PA-18-395 PA-18-591	This NOSI highlights the urgent need for social, behavioral, economic, health communication, and epidemiologic research relevant to the 2019 Novel Coronavirus (SARS-CoV-2) and COVID-19. This NOSI encourages urgent competitive supplements and administrative supplements to existing longitudinal studies that address key social and behavioral questions related to the COVID-19 pandemic, including adherence to and transmission mitigation from various containment and mitigation efforts; social, behavioral, and economic impacts from these containment and mitigation efforts; and downstream health impacts resulting from these social, behavioral, and economic impacts, including differences in risk and resiliency based on gender, race and ethnicity, socioeconomic status, and other social determinants of health. Applications in response to this NOSI must be submitted using the following targeted funding opportunities or subsequent re-issued equivalents: PA-18-935, PA-18-591.	Proposals accepted on a rolling basis	Up to \$100,000 per year, for up to 2 years	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-097.html">https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-097.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section II. Award 1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-591.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/pa-18-591.html#_Section II. Award 1</a>



42.	Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19)	NOT-HL-20-004 PA-18-591 PA-18-935	<p style="text-align: center;"><b>NIH</b></p> <p>NIDCD is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) in relation to NIDCD’s scientific mission areas of hearing, balance, taste, smell, voice, speech and language. n order to rapidly improve our understanding of the infection of SARS-CoV-2 and of COVID-19, NIDCD is encouraging the submission of applications for supplements to active NIDCD grants to address the pathology, prevention, diagnosis, sequelae, or treatment of COVID-19 directly related to NIDCD’s mission areas. Applications are expected to focus on immediate needs to help address the COVID-19 pandemic in a timely manner. Applications that are not responsive will be withdrawn without review. Applications for this initiative must be submitted using the solicitations PA-18-591 and PA-18-935.</p>	Proposals accepted on a rolling basis until 6/1/20	Up to \$125,000 for up to 1 year	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-DC-20-004.html">https://grants.nih.gov/grants/guide/notice-files/NOT-DC-20-004.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_Section_II._Award_1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section_II._Award_1</a>
43.	Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIDDK	NOT-DK-20-018 PA-18-935	<p>NIDDK is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19). NIDDK is particularly interested in projects focusing on the direct action of the virus on kidney, gastrointestinal tract function, and the endocrine/metabolic system, and the collection of biosamples that will inform the understanding of renal, gastrointestinal, and endocrine/metabolic sequelae of viral infection. Pilot clinical studies (observational and interventional) that support the understanding or treatment of COVID-19-related diseases within the mission of the NIDDK are also of interest. NIDDK will only consider applications that propose projects that may lead to rapid translation and impact in the COVID-19 emergency to be responsive to this NOSI. Applications for this initiative must be submitted using the PA-18-935.</p>	Proposals accepted on a rolling basis until 6/1/20	Up to \$500,000 for up to 1 year	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-DK-20-018.html">https://grants.nih.gov/grants/guide/notice-files/NOT-DK-20-018.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section_II._Award_1</a>

44.	Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)	NOT-DK-20-ES-20-015  PA-18-935  RFA-ES-19-011	<p style="text-align: center;"><b>NIH</b></p> <p>NIEHS is issuing this Notice of Special Interest (NOSI) to address the urgent need for mission-relevant research to understand the impact of environmental exposures on Coronavirus Disease 2019 (COVID-19) and its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies. Applications for this initiative must be submitted using opportunity PA-18-935.</p>	Proposals accepted on a rolling basis until 5/3/21	Dependent on proposal, for up to 2 year	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-ES-20-015.html">https://grants.nih.gov/grants/guide/notice-files/NOT-ES-20-015.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_Section II. Award 1</a>  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-19-011.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-19-011.html#_Section II. Award 1</a>
45.	Notice of Special Interest (NOSI): National Cancer Institute Announcement regarding Availability of Competitive Revision SBIR/STTR Supplements on Coronavirus Disease 2019 (COVID-19)	NOT-CA-20-043  PA-18-935	The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs at the National Cancer Institute (NCI) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for the development of prophylactic, therapeutic and diagnostic for Coronavirus Disease 2019 (COVID-19). To accelerate the development of promising technologies, the NCI encourages applications from small businesses with NCI-funded active SBIR/STTR awards for technologies that have a strong potential to be adapted/repurposed for use as a prophylactic, therapeutic or diagnostic tool for SARS-CoV-2 (COVID-19). Applications for this initiative must be submitted using opportunity PA-18-935.	Proposal Due: 6/25/20	Up to \$250,000 for Phase I and up to \$1 million Phase II (SBIR) and \$500,000 (STTR)	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-043.html">https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-043.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section II. Award 1</a>

46.	Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus	NOT-TR-20-016 PA-18-591	<p style="text-align: center;"><b>NIH</b></p> <p>NCATS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the COVID-19. NCATS is especially interested in research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines. A multi-organ on chip approach is strongly encouraged though not required. Please document access to a BSL-3 facility or include scientific justification for use of alternative facilities, for example using an engineered a COVID-19 pseudovirus that expresses the key surface Spike protein, which mediates its entry into cells. Applications for this initiative must be submitted using opportunity PA-18-591.</p>	Proposals accepted on a rolling basis until 1/25/22	Dependent on proposal, for up to 1 year	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-016.html">https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-016.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_SectionII.Award1</a>
47.	Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus	NOT-MH-20-047 PA-18-591 PA-18-935	<p>NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in research to strengthen the mental health response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and to future public health emergencies, including pandemics. NIMH is especially interested in research to provide an evidence base for how a disrupted workforce may adequately respond/adapt to and maintain services or provide additional care for new or increasing mental health needs, as well as to learn about the effects of the virus and public health measures to prevent spread of COVID-19 that may have an impact on mental health. Research addressing the intersection of COVID-19, mental health, and HIV treatment and prevention are also of interest to NIMH. Applications for this initiative must be submitted using opportunities PA-18-591 or PA-18-935.</p>	Proposals accepted on a rolling basis until 4/15/21	Dependent on proposal	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-MH-20-047.html">https://grants.nih.gov/grants/guide/notice-files/NOT-MH-20-047.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_SectionII.Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-935.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-18-935.html#_SectionII.Award1</a>

48.	Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus	NOT-TR-20-017  PA-18-135	<p style="text-align: center;"><b>NIH</b></p> <p>NCATS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the COVID-19. NCATS is especially interested in research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines. This Notice announces the availability of competitive revisions for investigators and institutions funded through The NIH Microphysiological Systems (MPS) Program; or SBIR/STTR-supported investigators, provided the award involves tissue chips; or Microphysiological systems programs from across NIH. PA-20-135 or its reissued equivalent must be used for submissions for this initiative.</p>	Proposals accepted on a rolling basis until 1/25/22	Dependent on proposal	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-017.html">https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-017.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_SectionII.Award1</a>
49.	Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities	NOT-TR-20-019  PA-18-591  PA-18-935	This NOSI is soliciting research in health disparity populations that - seeks to understand: 1) how state and local policies and initiatives mitigate or exacerbate disparities in health services use and health outcomes; 2) the role that community-level protective and resilience factors and interventions have in mitigating the effects of the sector disruptions that the COVID-19 outbreak causes; and 3) how behavioral and/or biological mechanisms may contribute to COVID-19 manifestations. Outcomes of interest include, but are not limited to, the COVID-19 incidence, prevalence, and mortality rates in defined populations; substance abuse and mental health effects; impact on chronic conditions; effects on severe maternal morbidity and mortality; and influence on access, utilization, and quality of health care (including needed medical care, medical treatments, and access to prescription drugs). Applications for this initiative must be submitted using opportunities PA-18-591 or PA-18-935.	Proposals accepted on a rolling basis until 5/1/21	Up to \$125,000 for up to 1 year	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-MD-20-019.html">https://grants.nih.gov/grants/guide/notice-files/NOT-MD-20-019.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_SectionII.Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-935.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-18-935.html#_SectionII.Award1</a>

50.	Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) Related to HIV Comorbidities, Coinfections, and Complications within NIDDK's Mission	NOT-TR-20-020 PA-18-935	<p style="text-align: center;"><b>NIH</b></p> <p>NIDDK is issuing this Notice of Special Interest (NOSI) in response to the urgent need for research on how coinfection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent for Coronavirus Disease 2019 (COVID-19), might affect HIV-associated comorbidities, coinfections, and complications (CCCs) within its mission. NIDDK supports biomedical research on diabetes and other endocrine and metabolic diseases; digestive diseases, nutritional disorders, and obesity; and kidney, urologic, and hematologic diseases. For this funding opportunity announcement, NIDDK is interested in studies to elucidate if COVID-19 might provoke or exacerbate noncommunicable gastrointestinal, liver, kidney/urological and metabolic/endocrine diseases in people with HIV (PWH) or worsen the consequences of viral hepatitis coinfection. Conversely, it is also important to elucidate whether people with HIV (PWH) with CCCs within the mission of NIDDK have different COVID-19 outcomes. Studies are expected to align with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR) in NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding. Applications for this initiative must be submitted using PA-18-935.</p>	Proposals accepted on a rolling basis until 6/1/20	Up to \$500,000 for up to 1 year	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-DK-20-020.html">https://grants.nih.gov/grants/guide/notice-files/NOT-DK-20-020.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section II. Award 1</a>
51.	Notice of Special Interest (NOSI): National Cancer Institute Announcement Regarding Availability of Urgent Competitive Revision and Administrative Supplements on Coronavirus Disease 2019 (COVID-19)	NOT-TR-20-042 PA-18-935 PA-18-591	The National Cancer Institute (NCI) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and the effects of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), on cancer, and vice versa. Topics of specific interest to NCI include understanding the basic mechanisms of interaction between SARS-CoV-2 and cancer cells, co-morbidities of cancer and SARS-CoV-2 infection (especially in disparately affected patient populations), and the impacts on treatment and clinical outcomes of SARS-CoV-2 infected persons in the context of cancer. Applications for this initiative must be submitted using opportunities PA-18-591 or PA-18-935.	Proposals accepted on a rolling basis until 6/25/20	Up to \$100,000 for up to 1 year	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-042.html">https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-042.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_Section II. Award 1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section II. Award 1</a>

52.	Notice of Special Interest (NOSI): Availability of Administrative Supplements and Urgent Competitive Revisions for Research on Stress Management in Relation to Coronavirus Disease 2019 (COVID-19)	NOT-AT-20-011 PA-18-935 PA-18-591	<p style="text-align: center;"><b>NIH</b></p> <p>NCCIH is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). Topics of specific interest for this NOSI include research on stress management strategies, including mind and body approaches, that individuals may engage in remotely to address stressors related to social distancing, as well as to address recovery and recurrence of symptoms during and after COVID-19 infections. . Applications for this initiative must be submitted using opportunities PA-18-591 or PA-18-935.</p>	Proposals accepted on a rolling basis until 10/6/20	Dependent upon proposal, for up to 1 year	<a href="https://grants.nih.gov/grants/guide/notice-files/not-at-20-011.html">https://grants.nih.gov/grants/guide/notice-files/not-at-20-011.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_Section II. Award 1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_Section II. Award 1</a>
53.	Notice of Special Interest (NOSI): Small Business Research and Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)	NOT-EB-20-006 PA-19-270 PA-19-272 PA-19-631	<p>NIBIB is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on SARS-CoV-2 and Coronavirus Disease 2019 (COVID-19). The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for accelerating the development, translation, and commercialization of technologies to address Coronavirus Disease 2019 (COVID-19). The NIBIB is seeking applications to develop life-saving technologies that can be ready for commercialization within one to two years. Example technologies include, but are not limited to:</p> <ul style="list-style-type: none"> <li>• Rapid point-of-care and home-based testing/diagnostics</li> <li>• Wearable, implantable, and remote sensors/imagers for physiological monitoring</li> <li>• Medical imaging technologies and algorithms/artificial intelligence (AI) for rapid detection, diagnosis, and monitoring of lung infection</li> </ul> <p>Applications for this initiative must be submitted using opportunities PA-19-270, PA-19-272, PA-19-631</p>	Proposals accepted on a rolling basis until 3/31/21	Dependent upon proposal	<a href="https://grants.nih.gov/grants/guide/notice-files/not-eb-20-006.html">https://grants.nih.gov/grants/guide/notice-files/not-eb-20-006.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-19-270.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/pa-19-270.html#_Section II. Award 1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-19-272.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/pa-19-272.html#_Section II. Award 1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-631.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-18-631.html#_Section II. Award 1</a>

54.	Notice of Special Interest (NOSI): Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)	NOT-EB-20-007 PAR-19-056 PAR-18-418 PAR-18-530 PAR-18-155 PAR-18-084 PAR-18-433 PAR-18-052	<p style="text-align: center;"><b>NIH</b></p> <p>NIBIB is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on SARS-CoV-2 and Coronavirus Disease 2019 (COVID-19). The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for accelerating the development, translation, and commercialization of technologies to address Coronavirus Disease 2019 (COVID-19). The NIBIB is seeking applications to develop life-saving technologies that can be ready for commercialization within one to two years. Example technologies include, but are not limited to:</p> <ul style="list-style-type: none"> <li>• Rapid point-of-care and home-based testing/diagnostics</li> <li>• Wearable, implantable, and remote sensors/imagers for physiological monitoring</li> <li>• Medical imaging technologies and algorithms/artificial intelligence (AI) for rapid detection, diagnosis, and monitoring of lung infection</li> </ul> <p>Applications in response to this NOSI must be submitted using one of the following target opportunities or subsequently reissued equivalents: PA-19-056, PA-18-418, PA-18-530, PA-20-155, PA-20-084, PA-20-433, PA-19-052</p>	Proposals accepted on a rolling basis until 3/31/21	Dependent upon proposal, for up to 2 years	<a href="https://grants.nih.gov/grants/guide/notice-files/not-eb-20-007.html">https://grants.nih.gov/grants/guide/notice-files/not-eb-20-007.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-19-056.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-19-056.html#_SectionII.Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-418.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/pa-18-418.html#_SectionII.Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-530.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-18-530.html#_SectionII.Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-155.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-20-155.html#_SectionII.Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-084.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-20-084.html#_SectionII.Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-433.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-18-433.html#_SectionII.Award1</a>
-----	---	---	---	---	--	---

55.	Notice of Special Interest (NOSI): Availability of Emergency Competitive Revision and Administrative Supplements on Biomedical Technologies for Coronavirus Disease 2019 (COVID-19)	NOT-EB-20-008 PA-20-135 PA-18-591	<p style="text-align: center;"><b>NIH</b></p> <p>NIBIB is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on SARS-CoV-2 and Coronavirus Disease 2019 (COVID-19). The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for accelerating the development, translation, and commercialization of technologies to address Coronavirus Disease 2019 (COVID-19). The NIBIB is seeking applications to develop life-saving technologies that can be ready for commercialization within one to two years. Example technologies include, but are not limited to:</p> <ul style="list-style-type: none"> <li>• Rapid point-of-care and home-based testing/diagnostics</li> <li>• Wearable, implantable, and remote sensors/imagers for physiological monitoring</li> <li>• Medical imaging technologies and algorithms/artificial intelligence (AI) for rapid detection, diagnosis, and monitoring of lung infection</li> </ul> <p>Applications in response to this NOSI must be submitted using one of the following target opportunities or subsequently reissued equivalents: PA-20-135, PA-18-591</p>	Proposals accepted on a rolling basis until 11/20/20	Dependent upon proposal, for up to 2 years	<a href="https://grants.nih.gov/grants/guide/notice-files/not-eb-20-008.html">https://grants.nih.gov/grants/guide/notice-files/not-eb-20-008.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_SectionII.Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_SectionII.Award1</a>
56.	Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19)	NOT-LM-20-010 PA-18-591	<p>NLM is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) in relation to NLM's strategic goal of fostering data driven research. In order to rapidly improve our understanding of the infection of SARS-CoV-2 and of COVID-19, NLM is encouraging the submission of applications for administrative supplements to active NLM R01 grants to address the following research areas of interest:</p> <ul style="list-style-type: none"> <li>• Methods for mining clinical data that can be used to identify or predict presence of COVID-19 in biomedical phenotype data, or other relevant topics such as discovery of risks for infection by SARS-Cov-2 viruses, use of standard terminologies for these viruses in federated health data sets</li> <li>• Public health surveillance methods that mine genomic, viromic, health data, environmental data and/or data from other pertinent sources such as social media, to identify spread and impact of SARS-Cov-2.</li> </ul> <p>Applications in response to this NOSI must be submitted using the opportunity PA-18-591.</p>	Proposal Due: 6/1/20	Up to \$75,000 for up to 1 year	<a href="https://grants.nih.gov/grants/guide/notice-files/not-lm-20-010.html">https://grants.nih.gov/grants/guide/notice-files/not-lm-20-010.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_SectionII.Award1</a>



57.	Notice of Special Interest (NOSI): Data Driven Research on Coronavirus Disease 2019 (COVID-19) (R21)	NOT-LM-20-011	<p style="text-align: center;"><b>NIH</b></p> <p>In order to rapidly improve our understanding of the infection of SARS-CoV-2 and of COVID-19, National Library of Medicine is encouraging the submission of R21 applications to address the following research areas of interest: 1. Methods for mining clinical data that can be used to identify or predict presence of COVID-19 in biomedical phenotype data, or other relevant topics such as discovery of risks for infection by SARS-Cov-2 viruses, use of standard terminologies for these viruses in federated health data sets; 2. Public health surveillance methods that mines genomic, viromic, health data, environmental data and/or data from other pertinent sources such as social media, to identify spread and impact of SARS-Cov-2. Applications are expected to focus on informatics and data science methods to help address the COVID-19 pandemic in a timely manner. Applications that are not responsive will be withdrawn without review.</p>	Proposal Due: 6/16/20	Dependent upon proposal	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-LM-20-011.html">https://grants.nih.gov/grants/guide/notice-files/NOT-LM-20-011.html</a>
58.	Notice of Special Interest: Availability of Administrative Supplements and Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIAAA	NOT-AA-20-011  PA-18-591  PA-18-935	<p>NIAAA is encouraging research in the following areas, including those that capitalize on existing research cohorts, to investigate urgent research questions of significance to the COVID-19 pandemic within the general population and among underserved populations, such as racial, ethnic and gender minorities, individuals with low socioeconomic status, and those who are incarcerated or homeless.</p> <p>Questions that may be addressed under this NOSI include, but are not limited to:</p> <ul style="list-style-type: none"> <li>• Are individuals who engage in high-risk drinking behaviors or with AUD more likely to engage in behaviors that increase risks for infection or transmission of SARS-CoV-2?</li> <li>• What is the influence of alcohol drinking history, patterns, amount, and duration on susceptibility to SARS-CoV-2 infection and COVID-19 prevalence, progression, and outcomes?</li> <li>• What are the common mechanisms of alcohol-associated Acute Respiratory Distress Syndrome (ARDS) and COVID-19-related ARDS? Applications in response to this NOSI must be submitted using the opportunities PA-18-591 and PA-18-935.</li> </ul>	Proposals accepted on a rolling basis until 4/15/21	Up to \$100,000 per year, for up to 2 year	<a href="https://grants.nih.gov/grants/guide/notice-files/not-aa-20-011.html">https://grants.nih.gov/grants/guide/notice-files/not-aa-20-011.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_Section_II._Award_1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_Section_II._Award_1</a>

59.	Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions and Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease (COVID-19) Public Health Needs	NOT-TR-20-028 PA-20-135 PA-18-591	<p style="text-align: center;"><b>NIH</b></p> <p>The National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for projects that address the COVID-19 Public Health Emergency. The Clinical and Translational Science Award (CTSA) Program is uniquely qualified to contribute to these efforts. NCATS is soliciting applications for Administrative Supplements (through PA-18-591) and Emergency Competitive Revisions (through PA-20-135) from current Clinical and Translational Science Award (CTSA) UL1 and U24 award recipients. Applications in response to this NOSI must be submitted using one of the following target opportunities or subsequently reissued equivalents. Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcements through the expiration date of this notice and designate "NOT-TR-20-028" (without quotation marks) in the Agency Routing Identifier field (Box 4b) of the SF424 (R&amp;R) Form as directed below.</p>	Proposals accepted on a rolling basis until 11/10/20	Up to \$100,000 per year, for up to 2 year	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-028.html">https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-028.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_SectionII.Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_SectionII.Award1</a>
60.	Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)	NOT-RM-20-015 PA-20-135	The Office of Strategic Coordination (OSC), which manages the Common Fund, is issuing this Notice of Special Interest (NOSI) to stimulate innovative research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the disease it causes, Coronavirus Disease 2019 (COVID-19). OSC seeks new, innovative perspectives and approaches to the prevention of, preparation for, or response to coronavirus SARS-CoV-2, domestically or internationally. The funding for this supplement is provided from the Coronavirus Aid, Relief, and Economic Security (CARES) Act, 2020. Applications in response to this NOSI must be submitted using the following targeted funding opportunity: PA-20-135 Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional), which is intended to provide funds for NIH grantees applying to expand the scope of their active grant.	Proposals accepted on a rolling basis until 6/19/20	Dependent upon proposal, for up to 1 year	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-RM-20-015.html">https://grants.nih.gov/grants/guide/notice-files/NOT-RM-20-015.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_SectionII.Award1</a>

61.	Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System	NOT-NS-20-051 PA-18-935 PA-18-591	<p style="text-align: center;"><b>NIH</b></p> <p>NINDS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects on the nervous system of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Research of interest must fall within NINDS’s scientific mission, which is to support basic, translational, and clinical neuroscience research to expand fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease. Applications in response to this NOSI must be submitted using the opportunities PA-18-935 and PA-18-591.</p>	Proposals accepted on a rolling basis until 4/14/21	Up to \$200,000, for up to 1 year	<a href="https://grants.nih.gov/grants/guide/notice-files/not-ns-20-051.html">https://grants.nih.gov/grants/guide/notice-files/not-ns-20-051.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_SectionII.Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_SectionII.Award1</a>
62.	Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements for Coronavirus Disease 2019 (COVID-19) Research within the Mission of NIDCR	NOT-DE-20-022 PA-18-591 PA-18-935	<p style="text-align: center;"><b>NIH</b></p> <p>NIDCR encourages submission of applications on the following topic areas of potentially <b>immediate and high impact</b> in combatting COVID-19.</p> <ul style="list-style-type: none"> <li>• Modifications to dental practice and/or treatment space to prevent aerosol and droplet pathogen transmission</li> <li>• Determination of the extent to which viral pathogens are transmitted via aerosol and droplet routes during treatment in dental settings</li> <li>• Design and implementation of strategies to achieve the <a href="#">Center for Disease Control and Prevention (CDC) second-tier Transmission-Based Precautions</a> in dental practice</li> <li>• Implementation of disinfection processes to ensure treatment spaces and equipment are devoid of transmissible viral pathogens</li> <li>• Development of interventions to protect health care workers, other front-line professionals, and patients from viral transmission</li> </ul> <p>Applications in response to this NOT must be submitted using the opportunities PA-18-935 and PA-18-591.</p>	Proposal due: 6/1/20, 11/2/20	Up to \$150,000, for up to 1 year	<a href="https://grants.nih.gov/grants/guide/notice-files/not-de-20-022.html">https://grants.nih.gov/grants/guide/notice-files/not-de-20-022.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_SectionII.Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_SectionII.Award1</a>

63.	Notice of Special Interest (NOSI): Infrastructure Access for Research on Coronavirus Disease 2019 (COVID-19) Conducted in the National Dental Practice-Based Research Network	NOT-DE-20-023 PAR-20-073	<p style="text-align: center;"><b>NIH</b></p> <p>National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) conducted in the National Dental Practice-Based Research Network (PBRN). NIDCR will place a high priority on topics that would be of <b>immediate and high impact</b> to protect and ensure the safety of personnel and patients in dental practices, prevent SARS-CoV-2 transmission, and improve detection and diagnosis of COVID-19. Successful X01 applicants will be given access to the National Dental PBRN infrastructure to support an individual project. Successful applications will utilize the resources of and be funded through the National Dental PBRN Administrative and Resource Center and/or National Coordinating Center for study planning and implementation. Applications in response to this NOSI must be submitted using the opportunity PAR-20-073.</p>	Proposal due: 6/1/20, 11/2/20	Dependent upon proposal, to 1 year	<p><a href="https://grants.nih.gov/grants/guide/notice-files/not-de-20-023.html">https://grants.nih.gov/grants/guide/notice-files/not-de-20-023.html</a></p> <p><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-073.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PAR-20-073.html#_SectionII.Award1</a></p>
64.	Notice of Special Interest (NOSI): Availability of Urgent Award for Competitive Revisions to IDeA-CTR Awards to Address the Need for Documenting 2019 Novel Coronavirus Disease (COVID-19)-Related Patient Outcomes	NOT-GM-20-033 PA-18-935	<p>NIGMS will accept applications for Competitive Revisions to active IDeA-CTR U54 awards to rapidly provide supplementary funds to create a registry of COVID-19 patients across IDeA states that includes a comprehensive set of deidentified clinical data elements. To reap the highest health benefit, the registry should be a secure clinical data portal that offers controlled access to clinicians providing care to patients and researchers studying the spread of SARS-CoV-2 and/or the pathology of COVID-19 for public health intervention measures. One award is anticipated, and the awardee is expected to collaborate with other IDeA-CTR awardees to ensure broad coverage of the registry. NIGMS strongly encourages applicants to make use of NIH Common Data Elements (CDEs) when developing their proposed registries: <a href="https://www.nlm.nih.gov/cde/index.html">https://www.nlm.nih.gov/cde/index.html</a>. Eligible applicants are awardees with an active NIGMS IDeA-CTR U54 award. The parent award must be active when the competitive revision application is submitted (e.g., within the originally reviewed and approved project period), regardless of the time remaining on the current project. Applications in response to this NOSI must be submitted to <a href="#">PA-18-935</a> "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)</p>	Proposal Due: 6/18/20	Up to \$400,000, for 1 year	<p><a href="https://grants.nih.gov/grants/guide/notice-files/NOT-GM-20-033.html">https://grants.nih.gov/grants/guide/notice-files/NOT-GM-20-033.html</a></p> <p><a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_SectionII.Award1</a></p>

65.	Request for Information (RFI): Strategy for Research in Coronavirus Serology Testing and Serological Sciences	NOT-CA-20-065	<p style="text-align: center;"><b>NIH</b></p> <p>This Notice is a time-sensitive Request for Information (RFI) inviting comments and suggestions on the topic of research approaches and priorities related to SARS-CoV-2 serology. On April 23, 2020, in response to the SARS-CoV-2 pandemic, Congress approved the Paycheck Protection Program and Health Care Enhancement Act, providing \$306M to the National Cancer Institute (NCI), working with the National Institute of Allergy and Infectious Disease (NIAID) and other parts of the NIH “to develop, validate, improve, and implement serological testing and associated technologies.” As a result of this Congressional mandate, the NCI and NIAID are soliciting community input via this RFI on the topic of research priorities for serological research and related technologies to address the immense public health and economic burdens created by COVID-19.</p> <p>NIAID has recently published a Strategic Plan for COVID-19 Research. This RFI is specifically related to the identification and delineation of national research priorities for serologic research and related technologies, as highlighted in the NIAID Strategic Plan.</p>	Response Due: 5/26/20	N/A	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-065.html">https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-065.html</a>
66.	Notice of Intent to Publish a Funding Opportunity Announcement for Serological Sciences Centers of Excellence	NOT-CA-20-066	<p>This Notice is associated with the COVID-19 Supplemental funding through the Paycheck Protection Program and Health Care Enhancement Act which directs the National Cancer Institute (NCI) of the NIH “to develop, validate, improve, and implement serological testing and associated technologies.” The NCI will publish an FOA to solicit applications to establish Serological Sciences Centers of Excellence of collaborating investigators and an RFA for research projects. The Centers and the projects will advance research opportunities to characterize the immune responses elicited by SARS-CoV-2 viral infection, especially as it relates to cancer patients. The Serological Sciences Centers of Excellence and research projects will be components of the Serological Sciences Network which, coordinated via the Frederick National Lab for Cancer Research.</p>	Estimated Proposal Due Date: 7/20/20	Up to \$1.5 million per year, for more than 1 year	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-066.html">https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-066.html</a>

67.	(*Closed) Notice of Special Interest: NIEHS Worker Training Program Coronavirus and Infectious Disease Response Training (Admin Supp Clinical Trial Not Allowed)	NOT-ES-20-014 PA-20-135 RFA-ES-19-003 RFA-ES-19-004 RFA-ES-19-009 RFA-ES-15-018	<p style="text-align: center;"><b>NIH</b></p> <p>The purpose of this supplement is to provide support for the conduct of worker-based training to prevent and reduce exposure of hospital employees, emergency first responders, and other workers who are at risk of exposure to Coronavirus through their work duties. The NIEHS Superfund Worker Training Program (WTP) will work collaboratively to develop and target safety and health training for those workers supporting the national Coronavirus response. Using our hazmat trainers' understanding of worker safety and health protection issues, knowledge of personal protective equipment (PPE) usage, and experience in training disaster workers, WTP will coordinate with the Centers for Disease Control and Prevention (CDC), the Occupational Safety and Health Administration (OSHA), and the National Institute for Occupational Safety and Health (NIOSH) to provide awardees with material to develop an evidence-based curriculum that addresses the science of Coronavirus (clinical symptoms, mode of transmission, persistence in the environment, and treatment); infection control and worker protection (isolation/quarantine and PPE); working in the contaminated environment (sampling and decontamination); and behavioral health.</p>	Closed: 4/24/20	Dependent upon proposal	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-ES-20-014.html">https://grants.nih.gov/grants/guide/notice-files/NOT-ES-20-014.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_Section II. Award 1</a>  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-19-003.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-19-003.html</a>  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-19-004.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-19-004.html</a>  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-19-009.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-19-009.html</a>  <a href="https://grants.nih.gov/grants/guide/rfa-files/rfa-es-15-018.html">https://grants.nih.gov/grants/guide/rfa-files/rfa-es-15-018.html</a>
-----	---	--	--	--------------------	-------------------------	---

68.	(*Closed) Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus	NOT-HG-20-030  PA-18-591  PA-18-935	<p style="text-align: center;"><b>NIH</b></p> <p>A better understanding of the host response, associated disease, and short- and long-term clinical outcomes of individuals infected with SARS-CoV-2. For NHGRI grantees only (including those with a current extension of funds or a no cost extension), we encourage the submission of applications for Competitive Revisions to support genomic research on SARS-CoV-2 and COVID-19 disease. Of particular interest are genomic studies utilizing generalized approaches that take advantage of human research or model systems to study the consequences of SARS-CoV-2 infection. Supported research is expected to guide and inform future efforts to diagnose, prevent, mitigate, or treat this viral infection. Applications in response to this NOSI must be submitted using one of the following target opportunities or subsequently reissued equivalents: <a href="#">PA-18-935</a> Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional) is intended to provide funds for NIH grantees applying to expand the scope of their active grant. <a href="#">PA-18-591</a> Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) is intended to provide funds for NIH grantees where the work proposed in the supplement is fully within the scope of the ongoing grant.</p>	Closed: 5/15/20	Up to \$250,000 per year, for up to 2 years	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-HG-20-030.html">https://grants.nih.gov/grants/guide/notice-files/NOT-HG-20-030.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html#_SectionII.Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html#_SectionII.Award1</a>
69.	(*Closed) Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01/R21 Clinical Trial Not Allowed)	PAR-20-178; 177	<p>The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). Areas of high priority include, but are not limited to, the following:</p> <ul style="list-style-type: none"> <li>• Development or improvement of clinical diagnostic tests for SARS-CoV-2 to increase the sensitivity and specificity</li> <li>• Development of SARS-CoV-2-specific or broadly protective coronavirus vaccine candidates including: novel antigen design strategies, novel platforms or delivery approaches, addition of adjuvants</li> </ul>	Closed: 4/30/2020	Dependent upon Proposal for up to 5 years  Dependent upon funding mechanism	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-178.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PAR-20-178.html#_SectionII.Award1</a> ;  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-177.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PAR-20-177.html#_SectionII.Award1</a>

NSF (1)						
70.	Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19)	NSF 20-052	In light of the emergence and spread of COVID-19 in the United States and abroad, the National Science Foundation (NSF) is accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge encourages the research community to respond to this challenge through <a href="#">existing funding opportunities</a> . In addition, we invite researchers to use the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency with regard to availability of or access to data, facilities or specialized equipment as well as quick-response research on natural or anthropogenic disasters and similar unanticipated events. Requests for RAPID proposals may be for up to \$200K and up to one year in duration. Well-justified proposals that exceed these limits may be entertained. All questions should be directed either to a program officer managing an NSF program with which the research would be aligned or to <a href="mailto:rapid-covid19@nsf.gov">rapid-covid19@nsf.gov</a> .	On-going	Up to \$200,000 for up to 1 year	<a href="https://www.nsf.gov/pubs/2020/nsf20052/nsf20052.jsp">https://www.nsf.gov/pubs/2020/nsf20052/nsf20052.jsp</a>  <a href="https://www.nsf.gov/pubs/policydocs/ppg19_1/index.jsp">https://www.nsf.gov/pubs/policydocs/ppg19_1/index.jsp</a>
OSTP (1)						
71.	COVID-19 Open Research Dataset (CORD-19)	N/A	In response to the COVID-19 pandemic, the Allen Institute for AI has partnered with leading research groups to prepare and distribute the COVID-19 Open Research Dataset (CORD-19), a free resource of over 51,000 scholarly articles, including over 40,000 with full text, about COVID-19 and the coronavirus family of viruses for use by the global research community. This dataset is intended to mobilize researchers to apply recent advances in natural language processing to generate new insights in support of the fight against this infectious disease. The corpus will be updated weekly as new research is published in peer-reviewed publications and archival services like bioRxiv, medRxiv, and others.	N/A	N/A	<a href="https://pages.semanticscholar.org/coronavirus-research">https://pages.semanticscholar.org/coronavirus-research</a>



<b>PCORI (1)</b>						
72.	COVID-19 Targeted PFA	N/A	The objectives of this funding announcement are to (1) strengthen the understanding of different approaches to improve the impact of COVID-19 on individuals, communities, healthcare providers, and healthcare systems; and (2) provide evidence to inform clinical and public health responses, decision making, and planning. This announcement has three targeted priority areas: (1) Adaptations to health care delivery, (2) Impact of COVID-19 on vulnerable populations, and (3) Impact of COVID-19 on healthcare workforce well-being, management, and training.	Proposal Due: 5/26/20	Up to \$5 million, for up to 2 years	<a href="https://www.pcori.org/sites/default/files/PCORI-2020-Cycle-2-COVID19-Targeted-PFA.pdf">https://www.pcori.org/sites/default/files/PCORI-2020-Cycle-2-COVID19-Targeted-PFA.pdf</a>
<b>SBA (1)</b>						
73.	Coronavirus (COVID-19): Small Business Guidance & Loan Resources	N/A	The U.S. Small Business Administration is offering designated states and territories low-interest federal disaster loans for working capital to small businesses suffering substantial economic injury as a result of the Coronavirus (COVID-19). Upon a request received from a state's or territory's Governor, the SBA will issue under its own authority, as provided by the Coronavirus Preparedness and Response Supplemental Appropriations Act that was recently signed by the President, an Economic Injury Disaster Loan declaration. Responses can be expected within 3 weeks. In addition to traditional SBA funding programs, the CARES Act established several new temporary programs to address the COVID-19 outbreak. These include the Paycheck Protection Program, EIDL Loan Advance, SBA Express Bridge Loans, and SBA Debt relief. Click <a href="#">here</a> for more details.	On-going until 6/30/20	Up to \$10,000 in short term Emergency Injury Disaster Loans	<a href="https://www.sba.gov/disaster-assistance/coronavirus-us-covid-19">https://www.sba.gov/disaster-assistance/coronavirus-us-covid-19</a>  <a href="https://www.sba.gov/page/coronavirus-covid-19-small-business-guidance-loan-resources#section-header-0">https://www.sba.gov/page/coronavirus-covid-19-small-business-guidance-loan-resources#section-header-0</a>
<b>OTHER (2)</b>						
74.	Biotechnology Innovation Organization (BIO) Coronavirus Hub to Facilitate Exchange of Supplies & Services	N/A	There is a dire need to ensure critical research and development programs can continue. To accomplish this, BIO created the <i>Coronavirus Hub</i> to connect companies with capacity and resources with those that need them. This new hub enables users to post requests for urgently needed items and announce the availability of supplies and capacity. The portal connects in real-time through customized and searchable postings.	On-going	N/A	<a href="https://hub.bio.org">https://hub.bio.org</a>

75.	BioOhio COVID-19 Resources Guide for Bioscience Organizations	N/A	<p style="text-align: center;"><b>OTHER</b></p> <p>Stay up-to-date with the latest information from government agencies, BioOhio members and partners, and other helpful organizations. If we follow the science, and take appropriate precautions, every one of us can play a role in keeping the infection curve down.</p>	On-going	N/A	<a href="https://www.bioohio.com/covid19/">https://www.bioohio.com/covid19/</a>
-----	---	-----	--	----------	-----	---